SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China
5 references·0 citing·28 second hopsampled
Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China (2019)Cost-effectiveness of Osimertinib as Firs…Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients WithEGFR-Mutated Advanced Non–Small Cell Lung Cancer (2018)Cost-effectiveness of Osimert…Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016)Global, regional, and nationa…Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting (2013)Health-Related Quality of Lif…Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? (2004)Use of Cost-Effectiveness Ana…Development of WHO guidelines on generalized cost-effectiveness analysis (2000)Development of WHO guidelines…EuroQol - a new facility for the measurement of health-related quality of life (1990)Measuring Health-Related Quality of Life (1993)Modeling Valuations for EuroQol Health States (1997)Health state utilities in patients with advanced non-small-cell lung cancer in China (2018)Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients (2018)The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer (2022)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Cost-Effectiveness in Health and Medicine (1996)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Bias in published cost effectiveness studies: systematic review (2006)Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold (2008)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)Bulletin of the World Health Organization (1955)Generalized cost-effectiveness analysis for national-level priority-setting in the health sector (2003)Generalisability in economic evaluation studies in healthcare: a review and case studies (2004)Methods for the Economic Evaluation of Health Care Programmes (2005)Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 (2012)Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 (2014)Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 (2016)Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017)Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 (2018)Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 (2024)Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves (2012)Thresholds for the cost–effectiveness of interventions: alternative approaches (2014)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer (2018)Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations (2019)Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer (2020)
this work references cited by second hop· second hop is a sample of the most-cited connections

References

  • 2016Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 20156,589 cited
  • 2004Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?790 cited
  • 2000Development of WHO guidelines on generalized cost-effectiveness analysis578 cited
  • 2013Health-Related Quality of Life and Utility in Patients with Advanced Non–Small-Cell Lung Cancer: A Prospective Cross-Sectional Patient Survey in a Real-World Setting147 cited
  • 2018Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients WithEGFR-Mutated Advanced Non–Small Cell Lung Cancer124 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work